Lin Ming-Yen, Chiu Yi-Wen, Chang Jung-San, Lin Hung-Lung, Lee Charles Tzu-Chi, Chiu Guei-Fen, Kuo Mei-Chuan, Wu Ming-Tsang, Chen Hung-Chun, Hwang Shang-Jyh
Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Faculty of Renal Care, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Kidney Int. 2015 Dec;88(6):1365-1373. doi: 10.1038/ki.2015.226. Epub 2015 Aug 5.
The evidence on whether Chinese herbal medicines affect outcome in patients with chronic kidney disease (CKD) is limited. Here we retrospectively explored the association of prescribed Chinese herbal medicine use and the risk of end-stage renal disease (ESRD) in patients with CKD. Patients with newly diagnosed CKD in the Taiwan National Health Insurance Research Database from 2000 to 2005 were categorized into new use or nonuse of prescribed Chinese herbal medicine groups. These patients were followed until death, dialysis initiation, or till the end of 2008. Among the 24,971 study patients, 11,351 were new users of prescribed Chinese herbal medicine after CKD diagnosis. Overall, after adjustment for confounding variables, the use group exhibited a significant 60% reduced ESRD risk (cause-specific hazard ratio 0.41, 95% confidence interval 0.37-0.46) compared with the nonuse group. The change was significantly large among patients using wind dampness-dispelling formulas (0.63, 0.51-0.77) or harmonizing formulas (0.59, 0.46-0.74), suggesting an independent association between specific Chinese herbal medicines and reduced ESRD risk. The findings were confirmed using propensity score matching, stratified analyses, and three weighting methods. However, dampness-dispelling and purgative formulas were associated with increased ESRD risk. Thus, specific Chinese herbal medicines are associated with reduced or enhanced ESRD risk in patients with CKD.
关于中草药是否会影响慢性肾脏病(CKD)患者的预后,相关证据有限。在此,我们回顾性地探讨了CKD患者使用中草药处方与终末期肾病(ESRD)风险之间的关联。将2000年至2005年台湾国民健康保险研究数据库中初诊为CKD的患者分为新使用或未使用中草药处方组。对这些患者进行随访,直至死亡、开始透析或至2008年底。在24971例研究患者中,11351例在CKD诊断后新使用了中草药处方。总体而言,在对混杂变量进行调整后,与未使用组相比,使用组的ESRD风险显著降低了60%(病因特异性风险比为0.41,95%置信区间为0.37 - 0.46)。在使用祛风除湿方剂(0.63,0.51 - 0.77)或调和方剂(0.59,0.46 - 0.74)的患者中,这种变化非常显著,表明特定的中草药与降低ESRD风险之间存在独立关联。使用倾向评分匹配、分层分析和三种加权方法对研究结果进行了验证。然而,祛湿和泻下类方剂与ESRD风险增加相关。因此,特定的中草药与CKD患者ESRD风险的降低或增加相关。